Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 13/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29131983 | 1.00 | PLK1 (0.42) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL31756841 | 1.00 | PLK1 (0.42) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL19447825 | 0.92 | PLK1 (0.39) | PLK1MEN1KMT2ADPP7 | |
| SCHEMBL23417972 | 0.90 | TLR2 (0.44) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL16757624 | 0.90 | MEN1 (0.43) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL16791114 | 0.90 | PLK1 (0.42) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL16757623 | 0.90 | MEN1 (0.43) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL29467645 | 0.90 | PLK1 (0.45) | PLK1TLR2DPP7 | |
| SCHEMBL21836141 | 0.89 | TLR2 (0.45) | PLK1MEN1KMT2ACA2TLR2 | |
| SCHEMBL16757612 | 0.89 | TLR2 (0.45) | PLK1MEN1KMT2ACA2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC | 2025-07-10 | — | — | US | disclosed |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4301415-A1 | BRANCHED LINKERS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. Scherer Technologies, LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117279662-A | Branched linkers for antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022187370-A1 | BRANCHED LINKERS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220241423-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | PLK1 696/4885MEN1 1029/4885KMT2A 1187/4885 |
| US-12187745-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | PLK1 696/4885MEN1 1029/4885KMT2A 1187/4885 |
| US-20250223302-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | PLK1 696/4885MEN1 1029/4885KMT2A 1187/4885 |
| US-20220241423-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | PLK1 696/4885MEN1 1029/4885KMT2A 1187/4885 |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | PLK1 696/4885MEN1 1029/4885KMT2A 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.